Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies
Open Access
- 24 March 2023
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (3), e0283473
- https://doi.org/10.1371/journal.pone.0283473
Abstract
SARS-CoV-2 pandemic has profound impacts on human life and global economy since the outbreak in 2019. With the new variants continue to emerge with greater immune escaping capability, the protectivity of the available vaccines is compromised. Therefore, development a vaccine that is capable of inducing immunity against variants including omicron strains is in urgent need. In this study, we developed a protein-based vaccine BCVax that is consisted of antigen delta strain spike protein and QS21-based adjuvant AB801 in nanoparticle immune stimulation complex format (AB801-ISCOM). Results from animal studies showed that high level of anti-S protein IgG was induced after two doses of BCVax and the IgG was capable of neutralizing multiple variants of pseudovirus including omicron BA.1 or BA.2 strains. In addition, strong Th1 response was stimulated after BCVax immunization. Furthermore, BCvax with AB801-ISCOM as the adjuvant showed significant stronger immunity compared with the vaccine using aluminum hydroxide plus CpG 1018 as the adjuvant. BCVax was also evaluated as a booster after two prior vaccinations, the IgG titers and pseudovirus neutralization activities against BA.2 or BA.4/BA.5 were further enhanced suggesting BCVax is a promising candidate as booster. Taken together, the pre-clinical data warrant BCVax for further development in clinic.This publication has 56 references indexed in Scilit:
- Matrix-M™ adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in miceImmunologic Research, 2018
- Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigenProceedings of the National Academy of Sciences of the United States of America, 2017
- ISCOMATRIX Adjuvant Combines Immune Activation with Antigen Delivery to Dendritic Cells In Vivo Leading to Effective Cross-Priming of CD8+ T CellsThe Journal of Immunology, 2011
- On the dilution behaviour of immuno-stimulating complexes (ISCOMs).2006
- ISCOMs: an adjuvant with multiple functionsJournal of Leukocyte Biology, 1998
- The role of type‐1 and type‐2 T‐helper immune responses in HIV‐1 vaccine protectionJournal of Medical Primatology, 1998
- Influence of Quillaja saponaria Triterpenoid Content on the Immunomodulatory Capacity of Epstein–Barr Virus IscomsScandinavian Journal of Immunology, 1997
- In vitro activation of antigen-presenting cells (APC) by defined composition of Quillaja saponaria Molina triterpenoidsClinical and Experimental Immunology, 1996
- Influence of the particle size on the adjuvant effect of particulate polymeric adjuvantsVaccine, 1986